Variant Creutzfeldt-Jakob disease and the Canadian blood system after the tainted blood tragedy

Social Science and Medicine

Volumn 64, Issue 1, 2007, Pages 174-185

  Wilson, Kumanan ^a   Graham, Ian ^b   Ricketts, Maura ^c   Dornan, Christopher ^c   Laupacis, Andreas ^a   Hebert, Paul ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CARLETON UNIVERSITY   (Canada)

Author keywords

Blood safety; Canada; Cost effectiveness; Creutzfeldt Jakob disease; Policy analysis; Precautionary principle; Risk decision making

Indexed keywords

BLOOD; CREUTZFELDT JAKOB DISEASE; HEALTH AND SAFETY; INFECTIOUS DISEASE; RISK ASSESSMENT;

ARTICLE; AVERSION; BLOOD TRANSFUSION; CANADA; COST EFFECTIVENESS ANALYSIS; CREUTZFELDT JAKOB DISEASE; HEALTH CARE COST; HEALTH CARE POLICY; HEMATOLOGY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSTITUTIONAL CARE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT SAFETY; RECIPIENT; RESPONSE TIME; RISK REDUCTION; SYNTHESIS; SYSTEM ANALYSIS; VIRUS TRANSMISSION;

BLOOD BANKS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CANADA; CREUTZFELDT-JAKOB SYNDROME; DECISION MAKING; HEALTH POLICY; HUMANS; SAFETY MANAGEMENT;

CANADA; NORTH AMERICA;

HEPATITIS C VIRUS;

EID: 33751009663     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2006.08.023     Document Type: Article

References (54)

1. Aach R.D., Szmuness W., Mosley J.W., Hollinger F.B., Kahn R.A., Stevens C.E., et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The transfusion-transmitted viruses study. New England Journal of Medicine 304 17 (1981) 989-994
2. Alter H.J., Purcell R.H., Holland P.V., Alling D.W., and Koziol D.E. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. Journal of The American Medical Association 246 6 (1981) 630-634
3. AuBuchon J.P., and Petz L.D. Making decisions to improve transfusion safety. In: AuBuchon J., Petz L., and Fink A. (Eds). Policy alternatives in transfusion medicine (2001), AABB Press, Bethesda, MD
4. Bayer Advisory Council on Bioethics. Creutzfeldt-Jakob disease, blood and blood products: A bioethics framework (1998), Bayer Advisory Council on Bioethics, Ottawa
5. Bayer, R., & Feldman, E.A. (1999). Understanding the blood feuds. In F. E. A., B. R. (Eds.), Blood feuds. Aids, blood, and the politics of medical disaster. Oxford: Oxford University Press.
6. Blajchman M.A., Bull S.B., and Feinman S.V. Post-transfusion hepatitis: Impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group. Lancet 345 8941 (1995) 21-25
7. Canadian Blood Services. CBS response and action plan-summary. Performance review of Canadian blood services (2003), Canadian Blood Services
8. Canadian Blood Services. Safety of products. Rising to the challenge. A report to Canadians 2003/4 (2004), Canadian Blood Services Operations Division
9. Canadian Hemophilia Society. (2005). Report card on Canada's blood system 7 years after the Commission of Inquiry on the blood system in Canada. Blood Safety Committee of the Canadian Hemophilia Society.
10. Cashman N.R. New variant Creutzfeldt-Jakob disease and the Canadian blood supply: Scientific basis of risk (1999), Laboratory Centre for Disease Control
11. Conlan T.J., Riggle J.D., and Schwartz D.E. Deregulating federalism? The politics of mandate reform in the 104th Congress. Publius 25 3 (1995) 23-40
12. Council of Europe, Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfusion Medicine Reviews 11 3 (2001) 149-175
13. ElSaadany S., and Giulivi A. Comprehensive risk assessment for vCJD in France and other countries for Canadians and the Canadian blood supply (2000), Division of Blood Borne Pathogens, Health Canada, Ottawa
14. Expert Advisory Committee on Blood Regulation. Minutes. Item 2 (1998), Health Protection Branch, Health Canada, Ottawa
15. FDA. (January 2002). Guidance for industry. In F. a. D. A (Ed.), Revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. US Department of Health and Human Services, Center for Biologics Evaluation and Research (CBER).
16. Gilmore, N., & Somerville, M.A. (1999). From trust to tragedy: HIV/AIDS and the Canadian blood system. In B. R. Feldman, E. A. (Ed.), Blood feuds. Aids, blood and the politics of medical disaster. Oxford: Oxford University Press.
17. Goodnough L.T. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 40 12 (2000) 1522-1527
18. Hogwood B.W., and Gunn L.A. Models of policy making. Policy analysis for the real world (1984), Oxford University Press, Oxford
19. IBM Consulting. (2002). Executive summary. In performance review of Canadian blood services. Final Report.
20. Jenkins-Smith H.C., and Sabatier P.A. Evaluating the advocacy coalition framework. Journal of Public Policy 14 (1994) 175-203
21. Krever H. The Consequences of the Contamination of the blood Supply. Chapter 26. Commission of inquiry on the blood system in Canada. Final Report (1997), Canadian Government Publishing, Ottawa
22. Krever H. The blood system for the future. Chapter 40. Commission of inquiry on the blood system in Canada. Final Report (1997), Canadian Government Publishing, Ottawa
23. Krever H. Canada's rejection of surrogate testing. Commission of inquiry on the blood system in Canada. Final Report (1997), Canadian Government Publishing, Ottawa
24. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal 146 4 (1992) 473-481
25. Lee K. France acts on threat of BSE transmission by blood. The French blood transfusion authorities are banning donors who might have become exposed to BSE in the UK. The Scientist (2001) January 23
26. Llewelyn C.A., Hewitt P.E., Knight R.S., Amar K., Cousens S., Mackenzie J., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 9407 (2004) 417-421
27. Lomas J. Connecting research and policy. Canadian Journal of Policy Research (2000) 140-144
28. Medicare Payment Advisory Committee. (2001). Blood safety in hospitals and medicare inpatient payment. Report to the Congress.
29. Morris J. Defining the precautionary principle. In: Morris J. (Ed). Rethinking risk and the precautionary principle (2000), Butterworth-Heinemann, Oxford
30. Orsini M. The politics of naming, blaming and claiming: HIV, Hepatitis C, and the Emergence of Blood Activism in Canada. Canadian Journal of Political Science 35 3 (2002) 475-491
31. Pal L.A. Public policy analysis (1992), Nelson Canada, Scarborough, ON
32. Peden A.H., Head M.W., Ritchie D.L., Bell J.E., and Ironside J.W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 9433 (2004) 527-529
33. Picard A. The gift of death. Confronting Canada's tainted-blood tragedy (1998), Harper Collins, Canada
34. Picard A. RCMP Lay 32 charges in tainted-blood case. Globe and Mail (2002) November 21, 2002
35. Plotkin S.A. Lessons learned concerning vaccine safety. Vaccine 20 Suppl. 1 (2001) S16-S19 discussion S1
36. Prusiner S.B. Novel proteinaceous infectious particles cause Scrapie. Science 216 4542 (1982) 136-144
37. Sabatier P.A. Knowledge, policy-oriented learning, and policy change. An advocacy coalition framework. Knowledge: Creation, Diffusion, Utilization 8 (1987) 649-692
38. Sabatier P.A. The need for better theories. Theories of the policy process (1993), Westview Press, Boulder, CO
39. Sabatier P.A. Policy change over a decade or more. Policy change and learning. An advocacy coalition approach (1993), Westview Press, Boulder, CO
40. Slovic P. Perception of risk. Science 236 4799 (1987) 280-285
41. Stoto M.A. The precautionary principle and emerging biological risks: Lessons from swine flu and HIV in blood products. Public Health Report 117 6 (2002) 546-552
42. Upshur R.E. Are all evidence-based practices alike? Problems in the ranking of evidence. Canadian Medical Association Journal 169 7 (2003) 672-673
43. Vaughan P. Creutzfeldt-Jakob disease latest unknown in struggle to restore faith in blood supply. Canadian Medical Association Journal 155 5 (1996) 565-568
44. Weinberg P.D., Hounshell J., Sherman L.A., Godwin J., Ali S., Tomori C., et al. Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s. Annals of Internal Medicine 136 4 (2002) 312-319
45. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347 9006 (1996) 921-925
46. Wilson K., Code C., Dornan C., Ahmad N., Hebert P., and Graham I. The reporting of theoretical health risks by the media: Canadian newspaper reporting of potential blood transmission of Creutzfeldt-Jakob disease. BMC Public Health 4 1 (2004) 1
47. Wilson K., Code C., and Ricketts M.N. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: Systematic review of case-control studies. British Medical Journal j 321 7252 (2000) 17-19
48. Wilson K., and Hebert P.C. The challenge of an increasingly expensive blood system. Canadian Medical Association Journal 168 9 (2003) 1149-1150
49. Wilson K., Hebert P.C., Laupacis A., Dornan C., Ricketts M., Ahmad N., et al. A policy analysis of major decisions relating to Creutzfeldt-Jakob disease and the blood supply. Canadian Medical Association JournalCmaj 165 1 (2001) 59-65
50. Wilson K., MacDougall L., Pinard B., Amin M.A., Fergusson D., Graham I., et al. How should Canada fund the blood system? An evaluation of the chargeback proposal. Hospital Quarterly 6 3 (2003) 44-47
51. Wilson K., McCrea-Logie J., and Lazar H. Understanding the impact of intergovernmental relations on public health: Lessons form reform initiatives in the blood system and health surveillance. Canadian Public Policy 30 (2004) 177-194
52. Wilson K., and Ricketts M.N. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 44 10 (2004) 1475-1478
53. Wilson K., Wilson M., Hebert P.C., and Graham I. The application of the precautionary principle to the blood system: The Canadian blood system's vCJD donor deferral policy. Transfusion Medicine Review 17 2 (2003) 89-94
54. Wingspread conference participants. (1998). Wingspread statement on the precautionary principle. Paper read at Wingspread Conference, January 23-25 1998, at Racine, Wisconsin.